Literature DB >> 8246822

Vero toxins (Shiga-like toxins) produced by enterohemorrhagic Escherichia coli (verocytotoxin-producing E. coli).

Y Takeda1, H Kurazono, S Yamasaki.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8246822     DOI: 10.1111/j.1348-0421.1993.tb01681.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


× No keyword cloud information.
  11 in total

1.  Relationship of genetic type of Shiga toxin to manifestation of bloody diarrhea due to enterohemorrhagic Escherichia coli serogroup O157 isolates in Osaka City, Japan.

Authors:  Y Nishikawa; Z Zhou; A Hase; J Ogasawara; T Cheasty; K Haruki
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 2.  Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives.

Authors:  K Sandvig; B van Deurs
Journal:  EMBO J       Date:  2000-11-15       Impact factor: 11.598

3.  Comparison of a PCR-restriction fragment length polymorphism (PCR-RFLP) assay to pulsed-field gel electrophoresis to determine the effect of repeated subculture and prolonged storage on RFLP patterns of Shiga toxin-producing Escherichia coli O157:H7.

Authors:  Kensuke Shima; Yuluo Wu; Norihiko Sugimoto; Masahiro Asakura; Kazuhiko Nishimura; Shinji Yamasaki
Journal:  J Clin Microbiol       Date:  2006-09-13       Impact factor: 5.948

4.  A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.

Authors:  Kiyotaka Nishikawa; Koji Matsuoka; Eiji Kita; Noriko Okabe; Masashi Mizuguchi; Kumiko Hino; Shinobu Miyazawa; Chisato Yamasaki; Junken Aoki; Sachio Takashima; Yoshio Yamakawa; Masahiro Nishijima; Daiyo Terunuma; Hiroyoshi Kuzuhara; Yasuhiro Natori
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  Development of a PCR-restriction fragment length polymorphism assay for the epidemiological analysis of Shiga toxin-producing Escherichia coli.

Authors:  Kensuke Shima; Jun Terajima; Toshio Sato; Kazuhiko Nishimura; Kazumichi Tamura; Haruo Watanabe; Yoshifumi Takeda; Shinji Yamasaki
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

6.  Molecular analysis of non-O1, non-O139 Vibrio cholerae associated with an unusual upsurge in the incidence of cholera-like disease in Calcutta, India.

Authors:  C Sharma; M Thungapathra; A Ghosh; A K Mukhopadhyay; A Basu; R Mitra; I Basu; S K Bhattacharya; T Shimada; T Ramamurthy; T Takeda; S Yamasaki; Y Takeda; G B Nair
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

7.  Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice.

Authors:  A R Melton-Celsa; S C Darnell; A D O'Brien
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

8.  Proteasome inhibitors prevent cell death and prolong survival of mice challenged by Shiga toxin.

Authors:  Takayuki Hattori; Miho Watanabe-Takahashi; Nobumichi Ohoka; Takashi Hamabata; Koichi Furukawa; Kiyotaka Nishikawa; Mikihiko Naito
Journal:  FEBS Open Bio       Date:  2015-06-12       Impact factor: 2.693

9.  A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo.

Authors:  Tao Li; Wei Tu; Yuenan Liu; Peng Zhou; Kun Cai; Zhan Li; Xiong Liu; Nianzhi Ning; Jie Huang; Shenghan Wang; Jian Huang; Hui Wang
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

10.  Evaluation of recombinant forms of the shiga toxin variant Stx2eB subunit and non-toxic mutant Stx2e as vaccine candidates against porcine edema disease.

Authors:  Toshio Sato; Takeshi Matsui; Eiji Takita; Yumiko Kadoyama; Sou-Ichi Makino; Ko Kato; Kazutoshi Sawada; Takashi Hamabata
Journal:  J Vet Med Sci       Date:  2013-07-03       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.